Haitao Pan, PhD
Haitao Pan, PhD

Haitao Pan, PhD

Assistant Member, St. Jude Faculty

Departments

Education

PhD - Graduate School of Biomedical Sciences, The University of Texas Health Science Center MD Anderson Cancer Center, Houston Texas
PhD - Fourth Military Medical University, Xi’an Shaanxi, China
MS - Xi’an University of Electronic Science and Technology (Xidian) , Xi’an Shaanxi, China

Research Interests

  • Bayesian Adaptive Clinical Trials Design
  • Nonparametric Bayesian Modelling
  • Statistical Computation
  • Longitudinal Data Analysis

Selected Publications

Kejian W, Qingbo Z, Chanjun L, Ling W, Chen L, Pan H*, Jielai X*. Some Statistical Considerations in Analytical similarity Assessment of Biosimilar Studies. Chinese Journal of Health Statistics 35(3):344-348, 2018. (*Corresponding author) (in Chinese)

Zhou H, Murray TA, Pan H, Yuan Y. Comparative review of novel model-assisted designs for phase I clinical trials. Statistics in Medicine March 2018. DOI: 10.1002/sim.7674 PMID: 29682777

Pan H, Liu S, Miao D, Yuan Y. Sample size determination for mediation analysis of longitudinal data. BMC Medical Research Methodology March;18:32, 2018. https://doi.org/10.1186/s12874-018-0473-2

Pan H, Yuan Y. A default method to specify skeletons for Bayesian model averaging continual reassessment method for phase I clinical trials. Stat Med Jan 30;36(2):266-279, 2017. doi: 10.1002/sim.6941. Epub 2016 Mar 16. PubMed PMID: 26991076; PubMed Central PMCID: PMC5026535.

Zhao L, Pan H. Radiotherapy alone or concurrent chemoradaition for esophageal squamous cell carcinoma in elderly patients. Journal of Cancer Research and Clinical Oncology 2017.

Zhao L, Xu M, Jiang W, Pan H, Zang J, Luo S, Wang J, Zhou Y, Shi M. Induction chemotherapy for the treatment of non-endemic locally advanced nasopharyngeal carcinoma. Oncotarget Jan 24;8(4):6763-6774, 2017.

Pan H, Yuan Y, Xia J. A calibrated power prior approach to borrow information from historical data with application to biosimilar clinical trials. Journal of the Royal Statistical Society: Series C (Applied Statistics) 2016.

Chu Y, Pan H, Yuan Y. Adaptive dose modification for phase I clinical trials. Statistics in Medicine 35(20):3497-508, 2016.

Liu S, Pan H, Xia J, Huang Q, Yuan Y. Bridging continual reassessment method for phase I clinical trials in different ethnic populations. Statistics in Medicine 34(10):1681-94, 2015.

Pan H, Zhu C, Zhang F, Yuan Y, Zhang S, Zhang W, Li C, Wang L, Xia J. The Continual Reassessment Method for Multiple Toxicity Grades: A Bayesian Model Selection Approach. PLoS ONE 9(5), 2014.

Yang Y, Zhang YG, Lin GA, Xie HQ, Pan HT, Huang BQ, Liu JD, Liu H, Zhang N, Li L, Chen JH. Spinal Changes of a Newly Isolated Neuropeptide Endomorphin-2 Concomitant with Vincristine-Induced Allodynia. PLoS ONE 9(2):e89583, 2014.

Yang Y, Zhang YG, Lin GA, Xie HQ, Pan HT, Huang BQ, Liu JD, Liu H, Zhang N, Li L, Chen JH. The effects of different hyperbaric oxygen manipulations in rats after traumatic brain injury. Neuroscience Letters 563:38-43, 2014.

Pan H, Xie F, Liu P, Xia J, Ji Y. A phase I/II seamless dose escalation/expansion with adaptive randomization scheme (SEARS). Clinical Trials 11(1):49-59, 2014.

Pan H, Huang P, Wang Z, Wang L, Li C, Xia J. A Novel Bayesian Seamless Phase I/II Design. PLoS ONE 8(9), 2013.

Pan H, Ji Y, Chen Z, Li C, Xia J. The Choice Of Phase I Bayesian Adaptive Designs In China. International Journal of Drug Discovery 5(1):185-90, 2013.

Pan H, Li C, Wang L, Jiang Z, Xia J. A Three-Stage Bayesian Adaptive Phase I/II Design and Simulation Studies. Communications in Statistics - Simulation and Computation 43(2):254-68, 2013.

Last update: July 2018